KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Current Investments: 2011-2025

Historic Cash & Current Investments for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $281.2 million.

  • Supernus Pharmaceuticals' Cash & Current Investments fell 30.27% to $281.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 32.08%. This contributed to the annual value of $453.6 million for FY2024, which is 77.97% up from last year.
  • Supernus Pharmaceuticals' Cash & Current Investments amounted to $281.2 million in Q3 2025, which was down 46.20% from $522.6 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Cash & Current Investments' 5-year high stood at $522.6 million during Q2 2025, with a 5-year trough of $151.7 million in Q2 2023.
  • For the 3-year period, Supernus Pharmaceuticals' Cash & Current Investments averaged around $327.7 million, with its median value being $297.7 million (2024).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 57.97% in 2023, then soared by 128.93% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $339.7 million in 2021, then soared by 35.81% to $461.3 million in 2022, then tumbled by 44.75% to $254.9 million in 2023, then surged by 77.97% to $453.6 million in 2024, then slumped by 30.27% to $281.2 million in 2025.
  • Its last three reported values are $281.2 million in Q3 2025, $522.6 million for Q2 2025, and $463.6 million during Q1 2025.